(Total Views: 760)
Posted On: 02/15/2021 12:38:50 AM
Post# of 148899
It would be criminal and money taken right out of your back pocket if we were to be bought out by another Pharma.
I say another Pharma because Nader just said on his last press release we are going to build CYDY into a “ big Pharma not a little Pharma but a big Pharma”!
If you think about what you would lose even with that J&J prediction, it is just unbelievable to me that Nader or any stock holder could even fathom a buy out this year. It just doesn’t make sense.
Someone recently posted that a normal average P/E ratio for a Pharma is 34-75. Some college study came to that average. (Gilead is at 67). Do you have any idea how that factors out? Say we have sales of what Nader predicted this year at between 10-15 Billion dollars worth. Use 10 billion divided by 700,000,000 shares of stock and times that by both 34 and 75 and see what the range of our stock price is could be if sales really approach 10 billion. That is $14.29 a share times a P/E of 34 or 75 = $485.71 or $1,071.75.
Giving away our shares for $85 a share to someone doesn’t seem to lucrative. And $4 a share in cash in our pocket. Seems like we have been ripped off.
I don’t price company stock out for living or pretend to know everything there is to know about pricing a company stock. But with ranges possible like mid triple digit by years end or even two years if we have to wait for HIV approvals around the world because covid sales didn’t pan out to $10 billion. That seems pretty lucrative to wait for.
Then we haven’t even factored in all the other indication possibilities. When Nader said we would be a quadruple digit stock someday he wasn’t exaggerating. It’s just a matter of a few blockbuster approvals. Now that we aren’t going to sell our indications in licensing deals... We are going to be flush with monies. Just think of sales from Covid and maybe two more blockbusters like Nash and maybe Cancer.
Do you really want to sell out or approve a buy out? Not me!!!
I say another Pharma because Nader just said on his last press release we are going to build CYDY into a “ big Pharma not a little Pharma but a big Pharma”!
If you think about what you would lose even with that J&J prediction, it is just unbelievable to me that Nader or any stock holder could even fathom a buy out this year. It just doesn’t make sense.
Someone recently posted that a normal average P/E ratio for a Pharma is 34-75. Some college study came to that average. (Gilead is at 67). Do you have any idea how that factors out? Say we have sales of what Nader predicted this year at between 10-15 Billion dollars worth. Use 10 billion divided by 700,000,000 shares of stock and times that by both 34 and 75 and see what the range of our stock price is could be if sales really approach 10 billion. That is $14.29 a share times a P/E of 34 or 75 = $485.71 or $1,071.75.
Giving away our shares for $85 a share to someone doesn’t seem to lucrative. And $4 a share in cash in our pocket. Seems like we have been ripped off.
I don’t price company stock out for living or pretend to know everything there is to know about pricing a company stock. But with ranges possible like mid triple digit by years end or even two years if we have to wait for HIV approvals around the world because covid sales didn’t pan out to $10 billion. That seems pretty lucrative to wait for.
Then we haven’t even factored in all the other indication possibilities. When Nader said we would be a quadruple digit stock someday he wasn’t exaggerating. It’s just a matter of a few blockbuster approvals. Now that we aren’t going to sell our indications in licensing deals... We are going to be flush with monies. Just think of sales from Covid and maybe two more blockbusters like Nash and maybe Cancer.
Do you really want to sell out or approve a buy out? Not me!!!
(10)
(1)Scroll down for more posts ▼
